Nasdaq apls.

Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.

Nasdaq apls. Things To Know About Nasdaq apls.

WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.Apellis Pharmaceuticals (NASDAQ: APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.. Apellis Pharmaceuticals has announced that it ...value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...

May 18, 2023 · deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) develops innovative treatments for diseases with unmet needs. In 2023, the FDA approved Syfovre, the only treatment for geographic atrophy (GA), a ...Get 7 Days Free Sign In Sign In Topics

The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ...WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...

WALTHAM, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the ...

CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...

1832 Asset Management L.P. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 405.5% in the 2nd quarter, according to its most …View live Apellis Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, APLS financials and market news.WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) andReported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...Apr 7, 2023 · The firm decreased its portfolio allocation in APLS by 48.09% over the last quarter. GSAOX - Goldman Sachs Small Cap Growth Insights Fund holds 13K shares representing 0.01% ownership of the company.

The public float for APLS is 97.67M, and at present, short sellers hold a 19.04% of that float. On November 06, 2023, the average trading volume of APLS was 3.32M shares. APLS) stock’s latest price update. The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has dropped by -3.80 compared to previous close of 46.83.STOCKHOLM, Dec. 13, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today new data demonstrating that ...It is now at its lowest level since June of 2020: 1. That is not a pretty 2-year chart, and investors are inevitably wondering whether the stock can be expected to recover anytime soon, or if it ...Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75.APLS Latest Pre Market Trades About Latest Pre-Market Trades Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq …WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business …

Fintel reports that on May 8, 2023, Citigroup maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation.. Analyst Price Forecast Suggests 4.25% Downside. As of April ...

GA is an advanced form of age-related macular degeneration and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision... -April 17, 2023 at 07:01 am- MarketScreenerJPMorgan upgraded Apellis Pharmaceuticals (NASDAQ: APLS) to Overweight from Neutral, with a new price target of $81, up from $60 per share in a note Friday. Analysts told investors the Syfovre ...The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ...We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...Jan 27, 2023 · Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ... Since Friday, Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of safety events connected to Syfovre. Syfovre ...Find the latest press releases from Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.14 нояб. 2023 г. ... Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, ...

Apr 24, 2023 · The forecasts range from a low of 51.51 to a high of $148.05. The average price target represents a decrease of 4.25% from its latest reported closing price of 93.18. See our leaderboard of ...

Apellis Pharmaceuticals Stock Up 14.3 %. APLS stock traded up $7.71 during midday trading on Friday, hitting $61.58. The company’s stock had a trading volume of 5,431,264 shares, compared to its ...

WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...Dec 1, 2023 · During the recent session, Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares were 1.43 million, with the beta value of the company hitting 0.96. At the last check today, the stock’s price was $57.36, reflecting an intraday gain of 6.48% or $3.49. The 52-week high for the APLS share is $ ... Envestnet Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,305 shares of the company’s stock after acquiring an additional 561 shares during the quarter. Envestnet Asset Management […]3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its ...GA is an advanced form of age-related macular degeneration and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision... -April 17, 2023 at 07:01 am- MarketScreenerNov 22, 2023 · Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has dropped by -3.62 in relation to previous closing price of 49.36. Nevertheless, the company has seen a loss of -1.71% in its stock price over the last five trading days. Zacks Investment Research reported 2023-11-09 that FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating […] Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results.See historical performance and comparison. View Valuation. Research Apellis Pharmaceuticals' (Nasdaq:APLS) stock price, latest news & stock analysis. Find …

WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Find the latest analyst research for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with ...Instagram:https://instagram. best utility etftrading automationbest company to purchase gold and silvertoyota sports car supra Hedge funds poured into Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in even greater numbers during Q2, as the number of funds long APLS rose by 27% to reach a new all-time high and propel it to ...It is now at its lowest level since June of 2020: 1. That is not a pretty 2-year chart, and investors are inevitably wondering whether the stock can be expected to recover anytime soon, or if it ... leonard drstlnr CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals, Inc. (APLS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 60.83 +6.96 (+12.92%) As of 02:29PM EST. Market open. 1d. fidelity interest on uninvested cash WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to the consensus estimate of $99.05 million. Its revenue was up 400.5% on a year-over-year basis.